Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia

This publication has 14 references indexed in Scilit:

• Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit
  British Journal of Haematology, 2014
• Peripheral blood features of acute myeloid leukemia with myelodysplasia‐related changes developing in a patient with sickle cell anemia
  American Journal of Hematology, 2014
• Emerging science of hydroxyurea therapy for pediatric sickle cell disease
  Pediatric Research, 2013
• DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype
  Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012
• Development of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a patient with sickle Cell Anemia
  Clinical Medicine Insights: Oncology, 2012
• Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
  Journal of Clinical Oncology, 2011
• Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms
  Blood, 2010
• The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
  Blood, 2010
• The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up
  American Journal of Hematology, 2010
• Malignancy in patients with sickle cell disease
  American Journal of Hematology, 2003